Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARα selective activators- PPARα and PPARγ selectivity modulation

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 9, 2010, Pages 2933-2937

  Ye, Xiang Yang ^a   Chen, Stephanie ^a   Zhang, Hao ^a   Locke, Kenneth T ^a   O'Malley, Kevin ^a   Zhang, Litao ^a   Srivastava, Raijit ^a   Miao, Bowman ^a   Meyers, Daniel ^a   Monshizadegan, Hossain ^a   Search, Debra ^a   Grimm, Denise ^a   Zhang, Rongan ^a   Lippy, Jonathan ^a   Twamley, Celeste ^a   Muckelbauer, Jodi K ^a   Chang, Chiehying ^a   An, Yongmi ^a   Hosagrahara, Vinayak ^a   Zhang, Lisa ^a   Yang, T J ^a   Mukherjee, Ranjan ^a   Cheng, Peter T W ^a   Tino, Joseph A ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Activator; PPAR ; PPAR ; Selectivity modulation; Structure activity relationship

Indexed keywords

2 ARYL 4 OXAZOLYLMETHOXY BENZYLGLYCINE DERIVATIVE; 2 ARYL 4 THIAZOLYLMETHOXY BENZYLGLYCINE DERIVATIVE; CARBAMIC ACID; FENOFIBRATE; GLYCINE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; DRUG SELECTIVITY; DRUG SYNTHESIS; HAMSTER; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BINDING SITES; CRICETINAE; CRYSTALLOGRAPHY, X-RAY; GLYCINE; HUMANS; MALE; PPAR ALPHA; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 77950918081     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.03.019     Document Type: Article

References (40)

1. For general reviews on PPARs:. Torra I.P., Chinetti G., Duval C., Fruchart J.-C., and Staels B. Curr. Opin. Lipidol. 12 (2001) 245
2. Evans A.J., and Krentz A.J. Drugs R. D. 2 (1999) 75
3. Sternbach D.D. Annu. Rep. Med. Chem. 38 (2003) 71
4. Cheng P.T.W., and Mukherjee R. Mini-Rev. Med. Chem. 5 (2005) 741
5. Meinke P.T., Wood H.B., and Szewczyk J.W. Annu. Rep. Med. Chem. 41 (2006) 99
6. Isseman I., and Green S. Nature 347 (1990) 771
7. Lee S.S., Pineau T., Drago J., Lee E.L., Owens J.W., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., and Gonzalez F.J. Mol. Cell. Biol. 15 (1995) 3012
8. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease, NIH Consensus Development Conference: Triglyceride, High-density lipoprotein, and Coronary heart disease, JAMA 1993, 269, 505.
9. Dobiasova M., and Frohlich J. Clin. Biochem. 34 (2001) 583
10. G.N. Pierce, M. Nagano, P. Zahradka, N. Dhalla (Eds.), Kluwer Academic Publishers, 2003, pp 4-17.
11. Linsel-Nitschke P., and Tall A.R. Nature 4 (2005) 193
12. Li A.C., and Palinski W. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 1
13. Stienstra R., Mandard S., Patsouris D., Maass C., Kersten S., and Mu{combining double acute accent}ller M. Endocrinology 148 (2007) 2753
14. Bensinger S.J., and Tontonoz P. Nature 454 (2008) 470
15. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.-C. Circulation 98 (1998) 2088
16. Todd P.A., and Ward A. Drugs 36 (1988) 314
17. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. J. Med. Chem. 43 (2000) 527
18. Hulin B., McCarthy P.A., and Gibbs E.M. Curr. Pharm. Des. 2 (1996) 85
19. Spencer C.M., and Markham A. Drugs 54 (1997) 89
20. For PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events), see:. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., and Taton J. Lancet 366 (2005) 1279
21. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., Jure H., Larochellière R.D., Staniloae C.S., Mavromatis K., Saw J., Hu B., Lincoff A.M., and Tuzcu E.M. JAMA 299 (2008) 1561
22. Nissen S.E., Wolski K., and Topol E.J. JAMA 294 (2005) 2581
23. Devasthale P.V., Chen S., Jeon Y., Qu F., Ryono D., Wang W., Zhang H., Cheng L., Farrelly D., Golla R., Grover G., Ma Z., Moore L., Seethala R., Sun W., Doweyko A.M., Chandrasena G., Sleph P., Hariharan N., and Cheng P.T.W. Bioorg. Med. Chem. Lett. 17 (2007) 2312
24. Cheng, P. T. W.; Chen, S.; Devasthale, P.; Ding, C. Z.; Herpin, T. F.; Wu, S.; Zhang, H.; Wang, W.; Ye, X.-Y. WO 2004004665 A2; Chem. Abstr. 2004, 140, 111429.
25. 50 = 0.04 in the HEK functional assay).
26. Devasthale P.V., Chen S., Jeon Y., Qu F., Shao C., Wang W., Zhang H., Cap M., Farrelly D., Golla R., Grover G., Harrity T., Ma Z., Moore L., Ren J., Seethala R., Cheng L., Sleph P., Sun W., Tieman A., Wetterau J.R., Doweyko A., Chandrasena G., Chang S.Y., Humphreys W.G., Sasseville V.G., Biller S.A., Ryono D.E., Selan F., Hariharan N., and Cheng P.T.W. J. Med. Chem. 48 (2005) 2248
27. Li, J.; Kennedy, L. J.; Shi, Y.; Tao, S.; Ye, X.-Y.; Chen, S. Y.; Wang, Y.; Hernández, A. S.; Wang, W.; Devasthale, P. V.; Chen, S.; Lai, Z.; Zhang, H.; Wu, S.; Smirk, R. A.; Bolton, S. A.; Ryono, D. E.; Zhang, H.; Lim, N.-K.; Chen, B.-C.; Locke, K. T.; O'Malley, K. M.; Zhang, L.; Srivastava, R. A.; Miao, B.; Meyers, D. S.; Monshizadegan, H.; Search, D.; Grimm, D.; Zhang, R.; Harrity, T.; Kunselman, L. K.; Cap, M.; Kadiyala, P.; Hosagrahara, P.; Zhang, L.; Xu, C.; Li, Y.-X.; Muckelbauer, J. K.; Chang, C.; An, Y.; Krystek, S. R.; Blanar, M. A.; Zahler, R.; Mukherjee, R.; Cheng, P. T. W.; Tino, J. A. J. Med. Chem., accepted for publication. doi:10.1021/jm9016812.
28. PDB deposition number is 3KDU.
29. 3. Therefore this paper is focused on the results upon removal of the methyl group from the 5-position of the oxazole/thiazole.
30. Einsiedel J., Thomas C., Hubner H., and Gmeiner P. Bioorg. Med. Chem. Lett. 10 (2000) 2041
31. 50 values (μM) for PPARα or γ agonist activity were calculated as the concentration of the test ligand (μM) required for the half-maximal fold induction of HEK293 cells. The 'intrinsic activity' of a test ligand is defined as its activity at 1 μM (expressed as a percentage) relative to the activity of the primary standards at 1 μM. The maximal efficacy was measured in percentage related to the standards (fenofibrate at 100 μM is 100% for PPARα; rosiglitazone at 1 μM is 100% for PPARγ). See:. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. J. Biol. Chem. 270 (1995) 12953
32. see Ref. 6 and the references cited therein.
33. Compounds 2i and 2j have the (S)-configuration, as indicated in Scheme 1. We have found that their corresponding (R)-enantiomers are less active.
34. Pyruvate dehydrogenase kinase (PDK4) is an inhibitor of the pyruvate dehydrogenase complex and modulates oxidative metabolism of glucose. It is highly induced in liver and pancreatic islets by PPARα agonists, and serves as a PD marker for PPARα activity. See:. Liu P.C.C., Huber R., Stow M.D., Schlingmann K.L., Collier P., Liao B., Link J., Burn T.C., Hollis G., Young P.R., and Mukherjee R. J. Steroid Biochem. Mol. Biol. 85 (2003) 71
35. Sugden M.C., Bulmer K., and Holness M. J. Biochem. Soc. Trans. 29 (2001) 272
36. Wang P.-R., Guo Q., Ippolito M., Wu M., Milot D., Ventre J., Doebber T., Wright S.D., and Chao Y.-S. Eur. J. Pharm. 427 (2001) 285
37. ApoA-I is the major lipoprotein on HDL particles. In rodents, ApoA-I expression is down-regulated by treatment with PPARα activators (such as fibrates), which results in the reduction of HDL-c levels, whereas in humans, the expression of ApoA-I is up-regulated, which results in an increase in HDL-c levels. These opposite effects on HDL-c in rodents vesus humans have been well documented in the literature and are consistent with our observations. See:. Berthou L., Duverger N., Emmanuel F., Langouet S., Auwerx J., Guillouzo A., Fruchart J.-C., Rubin E., Denefle P., Staels B., and Branellec D. J. Clin. Invest. 97 (1996) 2408
38. Staels B., and Auwerx J. Atherosclerosis 137 (1998) s19
39. Vu-Dac N., Chopin-Delannoy S., Gervois P., Bonnelye E., Martin G., Fruchart J.-C., Laudet V., and Staels B. J. Biol. Chem. 273 (1998) 25713
40. Gan J., Harper T.W., Hsueh M.-M., Qu Q., and Humphreys W.G. Chem. Res. Toxicol. 18 (2005) 896